Significant reduction in lung volumes and/or diffusing capacity for CO (>40%) from baseline may annunciate overt bleomycin pulmonary toxicity. Risk of continuation vs. benefit of therapy with, and risk of withdrawal of the drug has to be discussed on a case-by-case baisis. Lower than normal results of PFT are also described as a late effet of treatments with bleomycin (PMID 26422284)